Managing complicated, recurrent vulvovaginal candidiasis (RVVC) can be, well, complicated. Join Dr. Jack Sobel for his seminal presentation on the challenges of VVC and RVVC, the role of fluconazole, and what makes RVVC so complicated. He’ll also discuss new therapies on the horizon that may finally provide the answer to achieving greater recurrence-free rates for millions of women.
Riding the Wave of Change in Managing Vulvovaginal Candidiasis—Adapting to a New Era
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Riding the Wave of Change in Managing Vulvovaginal Candidiasis—Adapting to a New Era
closeCME/CE Broadcast Replay
Restart
Resume
Share this program on:
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Comments
Overview
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Jack David Sobel, MD
Dean of the School of Medicine
Professor of Internal Medicine (Infectious Disease) and Obstetrics and Gynecology
Wayne State University,
Detroit, MIConsulting Fees: Mycovia Pharmaceuticals, SCYNEXIS
Royalty: UpToDateReviewers/Content Planners/Authors:
- Sean Barrett has nothing to disclose.
- Amanda Hilferty has nothing to disclose.
- William Mencia, MD, FACEHP, CHCP, has nothing to disclose.
- Robert S. Schneider, MSW, has nothing to disclose.
- Jane R. Schwebke, MD, has disclosed the following:consulting fees for Hologic, and Talis; contracted research for BD Diagnostics, Hologic, Lupin, Mycovia Pharmaceuticals, and SCYNEXIS; and ownership interest with Talis.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Describe the symptoms, exam findings, and diagnostic testing for vulvovaginal candidiasis (VVC)
- Define the criteria by which VVC infections are defined as “uncomplicated” or “complicated”
- Describe advantages/limitations of existing and novel therapeutic interventions for VVC
Target Audience
This activity is designed to meet the educational needs of physicians, nurse practitioners, physician assistants, nurses, and certified nurse midwives in the fields of obstetrics and gynecology, family practice, and internal medicine.
Accreditation and Credit Designation Statements
Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Global Learning Collaborative designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Provider
Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.
Commercial Support
This activity is supported by an independent educational grant from SCYNEXIS.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Publication Dates
Release Date:
Expiration Date:
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
Managing complicated, recurrent vulvovaginal candidiasis (RVVC) can be, well, complicated. Join Dr. Jack Sobel for his seminal presentation on the challenges of VVC and RVVC, the role of fluconazole, and what makes RVVC so complicated. He’ll also discuss new therapies on the horizon that may finally provide the answer to achieving greater recurrence-free rates for millions of women.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Jack David Sobel, MD
Dean of the School of Medicine
Professor of Internal Medicine (Infectious Disease) and Obstetrics and Gynecology
Wayne State University,
Detroit, MIConsulting Fees: Mycovia Pharmaceuticals, SCYNEXIS
Royalty: UpToDateReviewers/Content Planners/Authors:
- Sean Barrett has nothing to disclose.
- Amanda Hilferty has nothing to disclose.
- William Mencia, MD, FACEHP, CHCP, has nothing to disclose.
- Robert S. Schneider, MSW, has nothing to disclose.
- Jane R. Schwebke, MD, has disclosed the following:consulting fees for Hologic, and Talis; contracted research for BD Diagnostics, Hologic, Lupin, Mycovia Pharmaceuticals, and SCYNEXIS; and ownership interest with Talis.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Describe the symptoms, exam findings, and diagnostic testing for vulvovaginal candidiasis (VVC)
- Define the criteria by which VVC infections are defined as “uncomplicated” or “complicated”
- Describe advantages/limitations of existing and novel therapeutic interventions for VVC
Target Audience
This activity is designed to meet the educational needs of physicians, nurse practitioners, physician assistants, nurses, and certified nurse midwives in the fields of obstetrics and gynecology, family practice, and internal medicine.
Accreditation and Credit Designation Statements
Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Global Learning Collaborative designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Provider
Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.
Commercial Support
This activity is supported by an independent educational grant from SCYNEXIS.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Publication Dates
Release Date:
Expiration Date:
Presenters
Facebook Comments